Deal Watch: BioLineRx, Ono, Vedantra Ink Separate Cancer Immunotherapy Pacts
BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.
You may also be interested in...
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Poland’s Ryvu To Feed Galapagos’ R&D Effort
Ryvu Therapeutics has added to its drug discovery collaborators with an early-stage deal with Belgium’s Galapagos.
PureTech Health: Applying Deep Thinking And Business Acumen
Targeting the age-dependent decline in immune function is the aim of a new PureTech Health subsidiary, resTORbio, that has licensed two clinical-stage mTORC1 inhibitors from Novartis.